Shots:
- Samsung Bioepis & Organon have expanded their development & commercialization agreement for Pyzchiva, a biosimilar version of Stelara (ustekinumab), with launch expected in 2026
- As per the deal, Organon will gain exclusive commercialization rights to Pyzchiva in Canada, while Samsung Bioepis retains responsibility for development, manufacturing, & regulatory activities.
- The addition of Pyzchiva expands the companies’ Canadian biosimilar collaboration portfolio from five to six products, incl. Hadlima (adalimumab), Brenzys (etanercept), Renflexis (infliximab), Aybintio (bevacizumab), and Ontruzant (trastuzumab)
Ref: Globenewswire | Image: Samsung Bioepis & Organon | Press Release
Related News: Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
